
The Promise of MRD Testing in Multiple Myeloma & CLL
While not yet mainstream in the community setting, measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.
Our guests—Drs. Rafael Fonseca and Tara Graff—discuss the benefits of MRD testing for these specific patient populations, the importance of training the multidisciplinary care team, and the promise of MRD testing to improve patient outcomes as its adoption continues to grow.
Guests:
Rafael Fonseca, MD…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.